Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Trial of Iberdomide in Combination With Daratumumab, BortEzomib and DexamethAsone in Patients With Newly Diagnosed Multiple MyeLoma (IDEAL)

NCT05392946 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT05392946
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05392946 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Trial of Iberdomide in Combination With Daratumumab, BortEzomib and DexamethAsone in Patients With Newly Diagnosed Multiple MyeLoma (IDEAL)
Lead sponsor
Mayo Clinic
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
August 11, 2022
Completion date
September 29, 2028
Enrollment
49 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

plasma cell myeloma